More Videos
|
CNBC'S MOST SHARED
- A Goldman Trading Scandal?
- Rich People With A Death Wish
- Facebook Director Sees 'Billions' in Revenue in 5 Years
- The Threat of Ballooning Pensions
- Lehman CEO: Firm Deserved Bailout or 'Wind Down'
- FedEx Sees Signs of a Turnaround: Report
- Texting And Driving Worse Than Drinking and Driving
- Market's Monday Blues
- Hey, What's Up Doc?
- Judge Gives Control of Jackson Estate to Executors
- March Lows Will Hold — So Buy Equities: Strategists
- Lacoste Runs Full Page Ad With Roddick Loss
- Brandt: Bing, The Little Search Engine That Couldn't
- 5-Star Manager's 5 Top Stocks
- Hey, What's Up Doc?
- Busch: Summertime Blues Hits Investors
- Chadwick: Recession and Scandals Pave the Way for Romney 2012
- Art Cashin: The S&P's 'Head and Shoulders' Number
- Michael Jackson: Death And Taxes
- Second Half: Wait For Pullbacks, Then Buy the Best
- Accused Ex-Goldman Sachs Programmer Out on Bail
- Discover Shares Fall on Word of Stock Offering
- California General Obligation Bond Rating Cut
- GM to Get Final $20 Billlion From US This Year
- World Trade Center Developer Threatens Arbitration
- The Weirdest Currencies on Earth
- Judge Gives Control of Jackson Estate to Executors
- Recession Special: Wine Cheaper Than Water!
RSS FEED
Text Size 
 |
CNBC.com |
In the note, Arnold names names. She thinks Pfizer [PFE
Loading...
()
] should buy Wyeth [WYE
Loading...
()
] or Amgen [AMGN
Loading...
()
]. Quite some time ago, Deutsche Bank analyst Barbara Ryan had suggested Pfizer look at Amgen as well.
Arnold claims Pfizer has four choices:
1. Go it alone.
2. Do a big deal.
3. Do a bunch of small deals.
4. "Divest, or even become an acquisition target." (I put the fourth choice in quotes to make clear it's a direct quote from Arnold's note.)
Arnold argues that a big deal offers the clearest path toward a higher share price. By Arnold's calculation, "PFE value is $29 with a Wyeth deal (and average synergies) and $26 with Amgen." She says a Wyeth deal would add to earnings in the first year and an Amgen deal would boost profit in the second or third year.
The word she uses is "accretive," but I don't like that Wall Street word or the opposite one, "dilutive." In plain English, a deal adds to or subtracts from earnings. Arnold also names six other biotechs and eight "specialty pharmaceutical" companies that passed her team's screening process as potential PFE targets: Biogen Idec [BIIB
Loading...
()
], Celgene [CELG
Loading...
()
], Cubist [CBST
Loading...
()
], Genzyme [GENZ
Loading...
()
], Gilead Sciences [GILD
Loading...
()
], United Therapeutics [UTHR
Loading...
()
], Allergan [AGN
Loading...
()
], Cephalon [CEPH
Loading...
()
], Endo Pharmaceuticals [ENDP
Loading...
()
], Forest Laboratories [FRX
Loading...
()
], Medicines Co. [MDCO
Loading...
()
], Sciele Pharma [SCRX
Loading...
()
], Sepracor [SEPR
Loading...
()
] and Shire Pharmaceuticals [SHPGF
Loading...
()
].
If PFE doesn't make a big buy, Arnold believes the attractive dividend is at risk. At the analyst meeting, Pfizer's CFO said, "Barring a significant unforeseen event of size," the dividend can be maintained "at least at current levels."
But Arnold says, "Assuming historical levels of dividend increases (10 percent annually), PFE's free cash flow will fall to less than the dividend by 2013. This calls into question the sustainability of PFE's dividend (and dividend increases) and therefore of the stock price which it underpins."
At the meeting the CEO and CFO asserted that while they remain "open to everything," they just don't see a big acquisition that makes sense.
In her exclusive interview with Pfizer Chairman and CEO Jeff Kindler Wednesday, Maria Bartiromo asked him specifically about the idea of buying Amgen and generally about doing a "megamerger." You can watch the segments by clicking on these videos.
Credit Suisse makes a market in PFE and wants to do investment banking for the company. Separately, a Pfizer spokesman points out that the disclosures provided by Goldman Sachs, which I cited in yesterday's post, are outdated. A GS director is no longer on the Pfizer board.
Catherine Arnold is maintaining a neutral rating on PFE, but in today's note it sounds as if she's telling clients to sell it. "Pfizer shares are worth $21 in the current 'go it alone' scenario. Our price target is reduced from $26. We advocate avoiding shares of Pfizer," she writes.
Pfizer shares hit a new intra-day low this morning of $21.28 as of this writing.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes